Medtronic (MDT) Receives a Buy from Citi
Citi analyst Joanne Wuensch reiterated a Buy rating on Medtronic (MDT – Research Report) today. The company’s shares opened today at $86.31.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Wuensch covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Dexcom, and Medtronic. According to TipRanks, Wuensch has an average return of 6.9% and a 62.11% success rate on recommended stocks.
In addition to Citi, Medtronic also received a Buy from RBC Capital’s Shagun Singh Chadha in a report issued today. However, on June 6, Needham maintained a Hold rating on Medtronic (NYSE: MDT).
Based on Medtronic’s latest earnings release for the quarter ending April 25, the company reported a quarterly revenue of $8.93 billion and a net profit of $1.06 billion. In comparison, last year the company earned a revenue of $8.59 billion and had a net profit of $654 million
Read More on MDT:
Disclaimer & DisclosureReport an Issue
- Trump Trade: President said to weigh possible U.S. strike against Iran
- Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
- Medtronic initiated with an Outperform at Leerink
- Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)
- Medtronic plans to name new diabetes company ‘MiniMed’
